Michael Davidson/LinkedIn
Nov 23, 2025, 14:48
Michael Davidson: Why LDL Alone Isn’t Enough for CV Risk Reduction
Michael Davidson, CEO of NewAmsterdam Pharma, posted on LinkedIn:
”Today’s standard lipid-lowering therapies focus almost exclusively on LDL-C reduction. Yet across large-scale studies, only 20–35% of patients taking them are meeting their risk-based LDL-C goals, highlighting the need for additional therapies.
Additionally, to maximize cardiovascular risk reduction, we need to address additional factors like lipoprotein(a), small LDL particles, and ApoB.
Learn how we can broaden the approach to reducing cardiovascular risk.”
Read more here.
Stay updated wth Hemostasis Today.
-
Jan 10, 2026, 14:40Last day at ASH25 from Riten Kumar
-
Jan 10, 2026, 08:56Shivanand Kumatagi Reflects on His Visit to Rela Hospital
-
Jan 10, 2026, 08:48Mitchell Elkind: Why Is The American Heart Association Holding a Brain Health Symposium?
-
Jan 10, 2026, 08:41Fiona Robinson Invites You to NBDF Webinar on Research Grants
-
Jan 10, 2026, 08:30Melissa Korn Takes Front Page Award for Her WSJ Piece on Experiencing a Pulmonary Embolism
-
Jan 10, 2026, 08:20Aymar Akilimali on Malaria in the Democratic Republic of Congo
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek